Long-Term Effect of Epoetin Alfa on Clinical and Biochemical Markers in Friedreich Ataxia (P5.387)

Conclusions: Although results are not in favor of an effect of Epoetin alfa in FRDA, this is the largest trial testing its effect. It is still possible that Epoetin alfa may show some symptomatic effect on upper limbs performance. This study provides Class I evidence that Erythropoietin does not ameliorate VO2max in patients with FRDA.Disclosure: Dr. Sacca has received personal compensation activities with Novartis, Almirall, Genzyme, and TEVA a speaker, editorial work, and advisory boards. Dr. Puorro has nothing to disclose. Dr. Marsili has nothing to disclose. Dr. Antenora has nothing to disclose. Dr. Pane has nothing to disclose. Dr. Casali has nothing to disclose. Dr. Marcotulli has nothing to disclose. Dr. Defazio has nothing to disclose. Dr. Liuzzi has nothing to disclose. Dr. Tatillo has nothing to disclose. Dr. Cambriglia has nothing to disclose. Dr. Schiano di Cola has nothing to disclose. Dr. Giuliani has nothing to disclose. Dr. Guardasole has nothing to disclose. Dr. Salzano has nothing to disclose. Dr. Ruvolo has nothing to disclose. Dr. De Rosa has nothing to disclose. Dr. Cittadini has nothing to disclose. Dr. De Michele has nothing to disclose. Dr. Filla has nothing to disclose.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Sacc, F., Puorro, G., Marsili, A., Antenora, A., Pane, C., Casali, C., Marcotulli, C., Defazio, G., Liuzzi, D., Tatillo, C., Cambriglia, D., Schiano di Cola, G., Giuliani, L., Guardasole, V., Salzano, A., Ruvolo, A., De Rosa, A., Cittadini, A., De Michele Tags: Movement Disorders: Ataxia Source Type: research